TAGS: Rare Diseases | StartUps and SM... | Business Strategies

Mitochondrial Medicine Focus Drives NeuroVive Orphan Ambitions

19 May 2017 | **ANALYSIS**

by Mike Ward

@ScripMikeWard | mike.ward@informa.com

Executive Summary

Erik Kinnman, CEO of NeuroVive Pharmaceutical, spoke to *Scrip* about the company's work in mitochondrial medicine. The company aims to develop orphan drugs to treat rare genetic conditions and seek partners for its NASH and liver cancer projects.

NEUROVIVE'S CEO INTERVIEWED BY SCRIP

Underpinned by a profound understanding of genetic mitochondrial disorders, Swedish biotech **NeuroVive Pharmaceutical AB** is pursuing a two-pronged orphan and specialty pharma approach. According to CEO Erik Kinnman, while the company intends to develop orphan drugs to treat rare genetic mitochondrial disorders, it is looking for partners for its NASH (non-alcoholic steatohepatitis) and hepatocellular cancer programs.

NeuroVive is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. “We have two programs in the mitochondrial space and could take these orphan treatments into the market ourselves,” Kinnman noted.

The company’s lead program is NeuroSTAT, which is in early Phase II clinical development for the prevention of moderate to severe traumatic brain injury (TBI). NeuroSTAT has orphan drug designation in Europe and in the US. As the company does not have expertise in marketing or distributing orphan medicines it could be interested in partners with such capabilities, added Kinnman.

Outside the orphan space, NeuroVive’s strategy for programs focused on larger indications is out-licensing at the preclinical phase. The company has a NASH program (NV556) available for partnering, with a clear signal in fibrosis, basic toxicology and scale up experience. A second program involves development of sanglifehrin-based compounds to treat hepatocellular carcinoma.

NEUROVIVE'S ERIK KINNMAN IN DISCUSSION WITH SCRIP *Scrip & EBD Group*

This interview was recorded at EBD Group's BIO-Europe Spring meeting in Barcelona, Spain, in March 2017.

From the editors of Start-Up

Topics

SUBJECTS

- Rare Diseases
- StartUps and SMEs
- Business Strategies
- Commercial

INDUSTRIES

- BioPharmaceutical

Related Companies

- NeuroVive Pharmaceutical AB

TAGS: Rare Diseases | StartUps and SM... | Business Strategies